ストックスクリーナーアプリを入手
13.96
6.15%
0.785
前日終値:
$13.18
開ける：
$13.255
24時間の取引高:
794.40K
Relative Volume:
0.39
時価総額：
$639.25M
収益：
$27.10M
当期純損益:
$-24.31M
株価収益率:
-16.83
EPS:
-0.83
ネットキャッシュフロー:
$-33.33M
1週間 パフォーマンス:
+41.46%
1か月 パフォーマンス:
+91.64%
6か月 パフォーマンス:
-5.85%
1年 パフォーマンス:
+155.29%
1日の値動き範囲:
$12.80
$14.08
1週間の範囲:
$9.53
$14.08
52週間の値動き範囲:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
名前
Capricor Therapeutics Inc
セクター
電話
(310) 358-3200
住所
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
CAPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
13.98 | 461.19M | 27.10M | -24.31M | -33.33M | -0.83 |
|
ONC
Beone Medicines Ltd Adr
|
256.05 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.36 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2213 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.59 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
497.16 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-20 | 開始されました | Roth Capital | Buy |
| 2024-10-21 | 開始されました | Piper Sandler | Overweight |
| 2024-05-17 | 開始されました | Oppenheimer | Outperform |
| 2024-01-05 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-12-26 | ダウングレード | Maxim Group | Buy → Hold |
| 2018-01-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-09-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-02-13 | 再開されました | Rodman & Renshaw | Buy |
| 2016-07-06 | 再開されました | H.C. Wainwright | Buy |
| 2016-06-15 | 開始されました | ROTH Capital | Buy |
すべてを表示
Capricor Therapeutics Inc (CAPR) 最新ニュース
Capricor Therapeutics (CAPR) Sees Borrow Rate Surge | CAPR Stock News - GuruFocus
Millennium Management LLC Acquires 12,285 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
BNP Paribas Financial Markets Reduces Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Two Sigma Investments LP Has $1.64 Million Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bank of America Corp DE Purchases 154,127 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor ... - Bluefield Daily Telegraph
Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Deutsche Bank AG Takes Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
(CAPR) Technical Data - news.stocktradersdaily.com
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Capricor Therapeutics Announces Equity Incentive Plan By Investing.com - Investing.com South Africa
CAPR Schedules Conference Call with CFO Bergmann | CAPR Stock Ne - GuruFocus
CAPR Schedules Conference Call with CFO Bergmann | CAPR Stock News - GuruFocus
Capricor Therapeutics Announces Equity Incentive Plan - Investing.com
Capricor Therapeutics Approves 2025 Equity Incentive Plan - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Connect - ACCESS Newswire
D. E. Shaw & Co. Inc. Purchases New Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Janus Henderson Group PLC Acquires New Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Capricor Therapeutics (NASDAQ:CAPR) Cut to “Sell” at Wall Street Zen - Defense World
Capricor Therapeutics’ Buy Thesis Ahead Of Deramiocel PDUFA Date (NASDAQ:CAPR) - Seeking Alpha
What is Roth Capital’s Estimate for CAPR Q2 Earnings? - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Reach Out - ACCESS Newswire
Roth Capital Initiates Coverage on Capricor Therapeutics (NASDAQ:CAPR) - Defense World
Analysts Set Expectations for CAPR FY2026 Earnings - Defense World
Uncertainties Regarding Capricor's CAP-1002 Approval (NASDAQ:CAPR) - Seeking Alpha
Capricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA Decision - Seeking Alpha
Capricor Therapeutics, Inc.’s (CAPR): Analysts See 489% Upside Potential - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Reach Out - ACCESS Newswire
Northern Trust Corp Boosts Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Stock (CAPR) Launch Hype Builds on Potential Breakthrough Therapy - Value The Markets
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2025 Earnings Call Transcript - MSN
Roth Capital Initiates Coverage on Capricor Therapeutics With Buy Rating - marketscreener.com
CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus
Capricor Therapeutics (CAPR): Roth Capital Sees Strong Growth Po - GuruFocus
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Acquired by The Manufacturers Life Insurance Company - Defense World
Research Analysts Offer Predictions for CAPR FY2025 Earnings - Defense World
How to Take Advantage of moves in (CAPR) - news.stocktradersdaily.com
Price T Rowe Associates Inc. MD Invests $197,000 in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor signals readiness for deramiocel approval with $145M in cash and expanded commercial launch preparations - MSN
Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair - simplywall.st
Analysts Are Upgrading Capricor Therapeutics, Inc. (NASDAQ:CAPR) After Its Latest Results - Yahoo Finance
Capricor Therapeutics’ Earnings Call: Optimism Amid Challenges - TipRanks
Capricor Therapeutics Inc (CAPR) 財務データ
収益
当期純利益
現金流量
EPS
Capricor Therapeutics Inc (CAPR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Mar 03 '25 |
Option Exercise |
1.39 |
2,500 |
3,475 |
8,223 |
| Litvack Frank | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
25,000 |
34,750 |
132,382 |
| DUNBAR GEORGE W JR | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
11,306 |
| COLLIER EARL M JR | Director |
Feb 27 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
57,606 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Dec 13 '24 |
Option Exercise |
1.39 |
8,000 |
11,120 |
28,047 |
| Litvack Frank | Director |
Dec 03 '24 |
Option Exercise |
1.10 |
20,391 |
22,430 |
46,278 |
| Nippon Shinyaku Co Ltd | 10% Owner |
Sep 20 '24 |
Buy |
5.36 |
2,798,507 |
14,999,998 |
7,090,351 |
| Musket David B | Director |
Aug 07 '24 |
Option Exercise |
1.39 |
34,000 |
47,260 |
81,692 |
1.30%
3.35%
大文字化:
|
ボリューム (24 時間):